CLYBL and colorectal carcinoma: Therefore, screening for specific inhibitors of ClbP would be a viable approach in developing therapeutics that can suppress the production of colibactin, which in turn could potentially lower the risk of CRC within clb + individuals while minimizing the negative side effects that may be brought about by antibiotic treatments for eradicating enteric clb + strains.